Abstract The basal-like or basal phenotype (BP) class of breast cancers have recently attracted attention as a poor prognostic form of breast cancer. However, BP appears to encompass biologically and clinically heterogeneous tumours, resulting in a lack of consensus definition of BP. We analysed 48,000 gene transcripts in 132 invasive breast carcinomas to identify two novel genes (OATP2 and FABP7) significantly associated with BP [defined by cytokeratin (CK)5/6 and/or CK14 positivity]. Using a series of invasive breast carcinoma cases (n = 899), prepared as tissue microarrays, we assessed OATP2 and FABP7 protein expression using immunohistochemistry to investigate associations with clinicopathological variables, patients' outcome and ability to refine BP classification. A total of 7.9 and 15.6% cases were OATP2 and FABP7 positive, respectively. OATP2 was associated with tumours of high histological grade (p \ 0.01), ER and PgR negativity (p \ 0.01) and shorter breast cancer-specific survival (p = 0.04). FABP7 expression was associated with lower lymph node stage (p \ 0.01), ER and PgR negativity (p \ 0.01). BP tumours which were FABP7 positive had a significantly longer BCSS (p = 0.05) and disease-free survival (p = 0.01) compared with FABP7 negative basal tumours (p \ 0.01). OATP2 positive tumours were associated with adverse survival and increased risk of early recurrence. This study confirms the biological and clinical heterogeneity of the BP in breast cancer. We have identified a novel subgroup of basal tumours showing FABP7 expression that have significantly better clinical outcome. Further studies analysing the role of FABP7 are therefore warranted.
Introduction
Advances in the understanding of breast cancer molecular and genetic mechanisms have led to the realisation of the heterogeneity of the disease and the promise of a new era of individualised management for breast cancer patients. Microarray-based class discovery studies pioneered by Perou and colleagues [1] have demonstrated that breast cancer could be classified into molecularly distinct groups based upon global gene expression profiles and their similarity to those of normal cell counterparts. Their results have subsequently been confirmed and expanded by multiple independent studies [2] [3] [4] [5] . One of these biologically and clinically distinct groups, which has attracted attention in recent years as a molecularly distinct subtype of breast cancer with poor prognosis, is basal-like cancer [1, 3, 4, 6] . Basal-like cancers also show negativity for markers that are targeted by endocrine therapy [oestrogen receptor (ER) and progesterone receptor (PgR)] and Herceptin (HER2). In breast cancer, the class of tumours showing basal differentiation has been described more than three decades ago [7] . Furthermore, the expression of basal CKs in breast cancer and their association with poor prognosis has confirmed by several studies [8] [9] [10] [11] . However, basal-like class of tumours has recently received much attention after their identification in gene expression profiling (GEP) studies as a molecularly distinct subtype of breast cancer.
Although patients with basal-like tumours are generally characterised by shorter disease-free survival, high mortality rate and experience a unique pattern of distant metastasis [12, 13] , it must be noted that this is not always the case, as some authors have reported a heterogeneity within basal-like tumours and other studies have failed to show an association with poorer outcome [14] [15] [16] . Identification of the basal subset can be achieved by immunohistochemistry (IHC). Despite the claimed greater accuracy of identification using GEP [1] , the more practical and cheaper method of IHC is more suited to a routine clinical setting. However, the inherent heterogeneity of basal tumours [17] [18] [19] has resulted in a lack of robust definition of the basal phenotype in clinical diagnosis. In clinical practice, the 'triple-negative' designation based on negative expression of ER, PgR and HER2 has been adopted and promoted in some centres as a simple and pragmatic definition [20, 21] . In spite of this, recent studies have raised the issue that some basal CK expressing (CK5/ 6, 14, 17) tumours are positive for ER and HER2, questioning general validity of the triple-negative method [22] and its reliance on negative results without inclusion of positive entry criteria. Several studies have attempted to refine the classification of the group by using a broader range of markers including the basal cytokeratins 5/6 and 14 and other basal-associated markers such as epidermal growth factor receptor (EGFR), vimentin and P-cadherin [14, 23] .
Most IHC-based definitions use positive expression of basal CKs as the basis to define the basal group [12, 13, 15, [24] [25] [26] as additional markers have so far failed to refine further the identification of poor survival cases. Other authors argue that basal CKs are not always expressed by the basal-like group of tumours identified by gene analyses, and hence novel markers must be incorporated into its definition [27] .
The aim of this study was to determine and characterise the protein expression of two novel markers associated with basal CKs expression, identified from gene profiling analysis, in large well-characterised cohort of invasive breast tumours and to investigate their association with other clinicopathological variables, patients' outcome and their ability to refine the classification of the basal phenotype.
Methods

Patient samples
The patient cohort comprised 899 primary operable invasive breast carcinoma cases from women presenting between 1986 and 1993, selected from the well-characterised Nottingham-Tenovus Primary Breast Carcinoma Series. All patients had been assessed in a standardised manner for clinical history and tumour characteristics including age, menopause status, tumour type [28] , histological grade [29] , tumour size, tumour recurrence, presence of distance metastasis, lymph node status, vascular invasion and Nottingham Prognostic Index (NPI) [30] . Data relating to survival were collated in a prospective manner including breast cancer-specific survival (BCSS), defined as the interval (in months) from the date of the primary treatment to the time of death due to breast cancer, and disease-free interval (DFI), defined as the interval (in months) from the date of the primary treatment to the first loco-regional recurrence or distant metastasis. Patient management was based on tumour characteristics by NPI and hormone receptor status. Patients with an NPI score B 3.4 received no adjuvant therapy, those with a NPI score [ 3.4 received Tamoxifen if oestrogen receptor (ER) positive (±Zoladex if pre-menopausal) or classical cyclophosphamide, methotrexate and 5-fluorouracil if ER negative and fit enough to tolerate chemotherapy [31] .
The cohort of patients (n = 899) consisted of 621 patients aged over or equal to 50 years, and 278 under 50 years old. Disease characteristics varied amongst the cohort; at primary diagnosis, 196 (21.8%) were of grade 1; 301 (33.5%) of grade 2 and 392 (43.6%) of grade 3. A total of 561 (62.4%) patients had tumours larger than 1.5 cm and 246 (27.4%) had definite vascular invasion. Follow-up data were collected initially at 3 months, followed by intervals of 6 months and then 12 months (median 160 months; range 1-224 months). During this time, recurrence occurred in 394 (43.8%) cases, distant metastases in 115 (12.8%) cases and 278 (30.9%) patients died from breast cancer. The immunoreactivity, scoring and categorisation of oestrogen receptor (ER), progesterone receptor (PgR), cytokeratin (CK)5/6, CK14, CK18, CK19, HER2, p53, BRCA1, basal phenotype (BP) and triplenegative phenotype (TN) were defined in this series as previously described [21, [32] [33] [34] .
This research was approved by Nottingham Research Ethics Committee 2 under the title of ''Development of a molecular genetic classification of breast cancer''.
Transcript expression profiling
Total RNA was isolated from 128 frozen tumours retrieved from Nottingham Hospitals NHS Trust Tumour Bank between 1986 and 1992 as described [18, 35] . RNA integrity and genomic DNA contamination were analysed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Total RNA was biotin-labelled using the Illumina TotalPrep RNA Amplification kit (Ambion) following manufacturers instructions. Biotin-labelled cRNA (1.5 lg) was used for each hybridisation on Sentrix Human-6 BeadChips (Illumina, San Diego, CA, USA) in accordance with manufacturer's protocol (also described in [36] ). Illumina gene expression data containing 47,293 features were processed and summarised in the Illumina BeadStudio software. Analyses of the probe level data were performed using the beadarray Bioconductor package [37] . The expression data are deposited in ArrayExpress at the EBI with the accession number E-TABM-576 (http://www.ebi. ac.uk/miamexpress/).
Identification of novel genes associated with basal phenotype
Artificial Neural Networks (ANNs) were used to identify genes significantly associated with BP. The ANN modelling used a supervised learning approach, multi-layer perceptron architecture with a sigmoidal transfer function, where weights were updated by a back propagation algorithm [38, 39] . Learning rate and momentum were set at 0.1 and 0.5, respectively. The ANN architecture utilised five hidden nodes in the hidden layer and randomised initial weights. The output node was coded as 0 if a case was BP negative (n = 93), and 1 if BP positive (n = 35). Data consisted of 128 samples each with 47,293 corresponding variables specifying the Log10 expression ratio of each transcript. Prior to ANN training, the data were randomly divided into three subsets: 60% for training, 20% for testing (to assess model performance during the training process) and 20% for validation (to independently test the model on data completely blind to the model). This process of random sample cross-validation enabled the generation of confidence intervals for the predictions on a separate blind dataset, and therefore avoided over-fitting of the data.
The intensity of each gene was used as an individual input in an ANN model, creating n individual models, where n was the number of transcripts on the array (47,293). These n models were then split into three subsets (described above) and trained. This random resampling and training process was repeated 50 times to generate predictions and associated error values for each sample with respect to the validation (blind) data. Inputs were ranked in ascending order based on predictive error, and the gene that performed with the lowest error was selected for further training. Next, each of the remaining genes was sequentially added to the previous best gene, and was used in combination in a model, creating n -1 models each containing two genes as inputs. Training was repeated and performance evaluated. The model with the highest modelling performance was again selected and the process repeated creating n -2 models each containing three inputs. This process was repeated until no significant gain was evident from the addition of further inputs. This resulted in a final model containing those transcripts that most accurately classified the patients according to BP. Receiver Operating Characteristic (ROC) curves were generated to provide statistics regarding model sensitivity and specificity.
Immunohistochemistry
Breast cancer tissue microarrays (TMA) and whole breast cancer tissue sections were prepared and immunohistochemistry was performed employing the standard streptavidin-biotin complex method as previously described [31, 40] . Primary antibodies used were fatty acid-binding protein-7 (FABP7; 1:50; Abcam Ltd., Cambridge, UK) and organic anion transporting polypeptide 2 (OATP2; clone MDQ; 1:20, Abcam) for 45 min incubation. 3-3 0 Diaminobenzidine tetrahydrochloride (Dako liquid DAB plus, K3468, Dako, Denmark) was used as a chromagen. The TMA sections were counterstained with Mayer's haematoxylin. Positive controls for FABP7 (brain tissue) and OATP2 (liver tissue) were used according to the supplier's data sheet.
Immunohistochemical scoring
Immunoreactivity of OATP2 and FABP7 in the TMA cores was scored as percentage of cells stained. Only staining of the invasive malignant cells within the tissue cores was considered. TMAs were scored using high-resolution digital images (NanoZoomer; Hamamatsu Photonics, Welwyn Garden City, UK), at 920 magnification, using a webbased interface (Distiller; Slidepath Ltd., Dublin, Ireland). All samples were scored by one observer (HZ) and a proportion of these counter-scored by a further observer (ARG) to ensure reproducibility.
Statistical analysis
Statistical analysis was performed using SPSS v15.0 statistical software. Frequency histograms were examined to group the expression of the biomarkers into expression groups, which were used throughout the analyses. Chisquared analyses were used for inter-relationships between steroid receptor co-regulators and for comparison with patho-clinical parameters, steroid receptors and biomarkers. The Kaplan-Meier method was used for the calculation of survival curves and disease-free interval analyses. Cox proportional hazards model was used to test the statistical independence and significance of predictors on disease-free interval (DFI) and the breast cancer-specific survival (BCSS). A p value of \0.05 was considered significant.
Results
Novel transcripts associated with basal phenotype
In order to identify novel transcript associated with BP, the expression of 47,293 transcripts in 128 invasive breast carcinomas from gene microarray experiments [36] was analysed using an Artificial Neural Network (ANN) predictive algorithm. This approach stratified the transcripts on their ability to classify the BP (as defined by CK5/6 and 14 positivity [41] , n = 35) compared with non-basal tumours (n = 93). Figure 1 illustrates the top 21 transcripts according to BP status. Two of these transcripts, FABP7 and OATP2, showed significantly higher expression in tumours with BP compared with non-basal tumours and were therefore chosen for subsequent translational analysis in TMAs due to the availability of commercial antibodies suitable for immunohistochemistry.
Expression of OATP2 and FABP7 in breast tumours
Evaluation of OATP2 and FABP7 in whole breast cancer tissue sections (n = 20) demonstrated that OATP2 immunoreactivity was localised to the cytoplasm of invasive cells, malignant in situ components where present, vascular endothelial cells and fibroblasts within the tumour stroma (Fig. 2a, b) . FABP7 immunoreactivity was present in normal adipocytes of the interlobular breast stroma delineating the plasma membrane of the cells and staining the nuclei strongly. Normal ductal/acinar epithelial cells also showed positive nuclear and cytoplasmic FABP7 immunoreactivity with some vascular endothelial cells of small vessels and capillaries also positive (Fig. 2c) . Both the cytoplasm and nuclei of invasive breast carcinoma cells showed positive granular immunoreactivity for FABP7 ranging from weak to strong with some cases showing no immunoreactivity (Fig. 2d) .
In the TMA breast tumours series, both proportion and intensity of FABP7 and OATP2 immunoreactivity varied in the cohort. The numbers of informative cases for FAPB7 and OATP2 were 578 and 584, respectively. FABP7 and OATP2 expression was each categorised into two groups, based on the observations of the frequency histogram distributions (FAPBP7, negative/low cytoplasmic expression B60%, positive cytoplasmic expression [60%; OATP2, negative B15%, positive expression [15%). Using these cut-off points, a total of 90/578 (15.6%) cases showed strong FAPBP7 cytoplasmic immunoreactivity, whilst 46/ 584 (7.9%) cases showed positive cytoplasmic expression of OATP2. We also noted a small number of tumours (n = 34) that showed nuclear immunoreactivity for FABP7, but no correlation was found between FABP7 nuclear expression and any clinico-pathological parameters (data not shown).
Association of OATP2 and FABP7 with clinico-pathological parameters GMPR2  PFDN5  D2LIC  FUT8  SEMA3C  NDUFB8  DUSP4  LOC345754  STARD10  AREG  HIST1H2BM  PPP2R3A  SUPT5H  FLJ12661  DPAGT1  EHD1  VGLL1  OATP2  FABP7 Table 2 , p = 0.035), where negative FABP7 staining was associated with classical lobular and lobular mixed tumours. OATP2 and FABP7 expression was not associated with either tumour size, age at diagnosis or development of distant metastases.
Association of OATP2 and FABP7 with biomarkers OATP2 and FABP7 expression was compared with the expression of previously determined biomarkers, summarised in Table 3 . A highly significant inverse association between OATP2 and FABP7 was observed where 68/84 (81%) cases with negative/low expression for FABP7 were OATP2 positive (p \ 0.001).
Positive OATP2 protein expression was also significantly associated with the positive expression of basal CKs [CK5/6 (p = 0.001), CK14 (p \ 0.001) and CK17 (p = 0.002)], p53 (p = 0.037), p-cadherin (p = 0.012) and EGFR (p = 0.020). Positive OATP2 expression was further significantly associated with lack of ER (p \ 0.001) and PgR (p \ 0.001) expression but was not associated with HER2 (p = 0.565).
Strong FAPB7 immunoreactivity also showed a significantly positive association with the expression of basal CKs [CK5/6 (p = 0.025), CK14 (p = 0.001) and CK17 (p = 0.006)], positive EGFR (p = 0.035), P-cadherin (p = 0.002) and luminal cytokeratin CK18 (p = 0.026) expression. Similar to OATP2, strong FABP7 immunoreactivity was correlated with negative expression of steroid receptors ER (p = 0.002), PgR (p = 0.006) but likewise was not associated with HER2 (p = 0.647). There was also no association between OATP2 and FABP7 expression with CK7/8, CK19, caveolin 1, caveolin 2, smooth muscle actin or MIB1 (data not shown).
There was also a highly significant association observed between OATP2 and FABP7 with BP etiher defined as CK5/6 and/or CK14 positivity (p \ 0.001, Table 4 ) or with the inclusion of CK17 positivity (p \ 0.001, data not shown). Within the basal-like tumours only, OATP2 Table 4 ). However, there was no association with either OATP2 or FABP7 with the triple-negative phenotype (ER, PgR and HER2 negative; Table 4 ).
Association of OATP2 and FABP7 with patient outcome
Univariate survival analyses showed those tumours positive for OATP2 had a significantly poorer BCSS compared with OATP2-negative tumours (p = 0.042, Fig. 3a) . Although positive expression of OATP2 was not significantly correlated with DFI over the full follow-up period (p = 0.266, Fig. 3b) , there is clearly a dramatic difference in the probability of recurrence during the first 5 years where positive OATP2 expression is associated with a shorter DFI (p = 0.014). In contrast, strong immunoreactivity for FABP7 in breast cancer was associated with a trend for a longer BCSS, although this did not reach statistical significance (p = 0.052, Fig. 3c ). Furthermore, FABP7 was significantly correlated with DFI where a longer DFI was observed for those patients with tumours showing strong immunoreactivity for FABP7 (p = 0.019, Fig. 3d ).
Within the BP (defined as CK5/6 and CK14 positive), FABP7 expression significantly affected patient outcome. Basal-like tumours which showed strong expression for FABP7 had a significantly longer BCSS than FABP7-negative tumours showing BP (p = 0.006, Fig. 4a ). Similarly, FABP7 immunoreactivity was associated with a significantly longer DFI in breast tumours showing BP (p = 0.002, Fig. 4b ). There was no difference in BCSS or DFI in non-basal tumours with respect to FABP7 expression. OATP2 expression was not associated with either BCSS or DFI within the basal and non-basal tumours (data not shown).
In multivariate Cox-proportional hazards analysis, FABP7 expression was a significant predictor of longer DFI (p = 0.033) independent of tumour grade, size, lymph node stage, ER status and BP status (Table 5 ). There was also a strong trend for FABP7 expression to independently predict a longer BCSS (p = 0.052). 
Discussion
The basal-like type or BP of breast cancer has been subject to extensive investigation in recent years, mainly due to its association with poor patient survival [3, 13, 15, 21, 22, 41] . Despite this interest, there is currently no robust definition for designation of 'basal-like' or BP breast cancer in routine clinical practice; furthermore, tumours with a BP are also now recognised to exhibit heterogeneity [14, 22] . In this study, the protein expression of two novel markers associated with basal phenotype, identified by a gene profiling analysis, OATP2 and FABP7, were investigated in a large series of breast tumours. The expression of OATP2 was significantly associated with poor patient outcome. OATP2 has been found to be co-expressed at high levels in the placenta and the liver with breast cancer-resistance protein (BCRP), an ATPbinding cassette (ABC) protein [42] . BCRP, when overexpressed in vitro, has the ability to induce high levels of resistance to anti-cancer chemotherapy drugs such as anthracyclines, mitoxantrone and bisantrene [43] . It could be inferred therefore that overexpression of OATP2 in breast tumours may give the tumour some chemotherapyresistant properties. Unfortunately, the number of patients used in this study was not sufficient to investigate whether or not OATP2 had an effect on chemotherapy response and therefore further studies determining the expression of the marker in all patients who received chemotherapy and/or hormone therapy should be conducted.
FABP7 has previously been linked to BP of breast tumours in gene expression studies [3] , and the findings in this study confirm this association. However, protein expression of FABP7 in human breast cancer has not previously been investigated. FABP7 belongs to a group of proteins called Lipid-Binding Proteins (LBP), which are involved in the transportation and storage of fatty acids for metabolism [44] . Studies on FABP7 expression in the brain have demonstrated that it is linked with poorer survival in patients with glioblastomas [45, 46] , but the findings of this study showed that FABP7-positive breast tumours had longer BCSS and DFI, which appears independent of other known prognostic factors in breast cancer. Various in vitro studies of the FABP7 gene have concluded that it acts as an inhibitor of breast cancer cell growth, with inhibition of growth being proportional to the expression of the gene, thereby explaining its alternative name, mammary-derived growth inhibitor-related gene (MRG) [47] . We have observed that FABP7 is preferentially expressed by breast tumours exhibiting a basal phenotype and significantly associated with better outcome in this form of breast cancer. This incongruity could suggest that FABP7-positive tumours behave less aggressively particularly as FABP7 is known to inhibit cell growth [47] . It has been demonstrated that EGFR activation up-regulates FABP7 and induces its nuclear translocation in vitro. Inhibition of FABP7 expression in turn inhibits EGF-induced migration in glial cells, suggesting that EGFR-induced invasion properties are partly mediated by FABP7 [45] . The link between FABP7 and EGFR is of interest in breast carcinomas, especially the basal-like group, as EGFR has been identified by several publications to be one of the discriminating factors of this particular group [48] [49] [50] .
In conclusion, the study has demonstrated the biological, pathological and clinical features of FABP7 and OATP2 protein expression in human breast carcinoma and with respect to FABP7 particularly its relationship and significance in BP breast cancer [12, 13, 15, 17, 21, 22, 24, 27, 41, 51] . These novel biomarkers have significant associations, both independently and within the BP, on tumour behaviour, expression of other biomarkers and clinical outcome. Thus, this further study confirms the clinical importance of the BP, and that screening for these basal markers may be relevant to integral to determining the outcome of individual patients with this form of breast cancer. This study highlights an important niche in the literature where only a number of immune response markers in basal-like cancers have been previously identified that have an association with improved patient survival [52] . The identification of FABP7 through gene analyses and the analysis of its protein expression may suggest that novel markers may be able to differentiate between basal tumours associated with poor or favourable patient outcome. As a result, such markers need to be considered for incorporation into the definition of the basal phenotype, in the search for improved and robust ways to differentiate this group clinically. 
